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Proteomic peptide profiling for preemptive diagnosis of acute
graft-versus-host disease after allogeneic stem cell transplantation
EM Weissinger1, J Metzger2, C Dobbelstein1, D Wolff3, M Schleuning4, Z Kuzmina5, H Greinix5, AM Dickinson6, W Mullen7, H Kreipe8,
I Hamwi1, M Morgan9, A Krons2, I Tchebotarenko1, D Ihlenburg-Schwarz1, E Dammann1, M Collin6, S Ehrlich1, H Diedrich1, M Stadler1,
M Eder1, E Holler3, H Mischak2, J Krauter1 and A Ganser1
Allogeneic hematopoietic stem cell transplantation is one curative treatment for hematological malignancies, but is compromised
by life-threatening complications, such as severe acute graft-versus-host disease (aGvHD). Prediction of severe aGvHD as early as
possible is crucial to allow timely initiation of treatment. Here we report on a multicentre validation of an aGvHD-specific urinary
proteomic classifier (aGvHD_MS17) in 423 patients. Samples (n¼ 1106) were collected prospectively between day þ 7 and day
þ 130 and analyzed using capillary electrophoresis coupled on-line to mass spectrometry. Integration of aGvHD_MS17 analysis
with demographic and clinical variables using a logistic regression model led to correct classification of patients developing severe
aGvHD 14 days before any clinical signs with 82.4% sensitivity and 77.3% specificity. Multivariate regression analysis showed that
aGvHD_MS17 positivity was the only strong predictor for aGvHD grade III or IV (Po0.0001). The classifier consists of 17 peptides
derived from albumin, b2-microglobulin, CD99, fibronectin and various collagen a-chains, indicating inflammation, activation of T
cells and changes in the extracellular matrix as early signs of GvHD-induced organ damage. This study is currently the largest
demonstration of accurate and investigator-independent prediction of patients at risk for severe aGvHD, thus allowing preemptive
therapy based on proteomic profiling.
Leukemia (2014) 28, 842–852; doi:10.1038/leu.2013.210
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
one curative treatment for adult patients with high-risk acute
leukemia or severe hematopoietic failure syndromes. Overall
survival is about 40% (range 25–62%) for leukemia patients
depending on primary disease, stage, conditioning regimens1,2
and risk groups (range: 25% (high-risk leukemia) to 62% (good-risk
leukemia)),3 and about 90% for hematopoietic failure syndrome
patients.4–6 However, allo-HSCT is associated with major
complications, such as severe acute graft-versus-host disease
(aGvHD) and infections.7–9 Differential diagnosis of aGvHD from
treatment-related toxicities can be difficult and is mainly made
according to clinical symptoms and biopsies. Thus, a method is
urgently needed to diagnose early onset of aGvHD and to identify
patients at risk of developing severe GvHD in an observer-
independent, unbiased fashion. Depending on the type of
transplantation, patient age, the immunosuppressive prophylaxis
and the underlying disorders, 35–85% of transplanted patients
develop aGvHD.7,10,11 First-line therapy of aGvHD consists of
steroids resulting in a response rate of about 70% for patients with
aGvHD grade I or II without significant increase of mortality.10
In contrast, patients developing aGvHD grades III or IV have a
mortality risk of about 80–90% due to aGvHD-specific organ
dysfunction or concomitant infections.12 Recently, proteome
analysis of body fluids using capillary electrophoresis (CE) coupled
on-line to mass spectrometry (MS) to define differentially excreted
peptides has been shown to be a powerful new diagnostic tool in a
variety of diseases and is broadly applicable.13–17 CE-MS has been
applied to identify biomarkers for early detection of aGvHD in
patients undergoing allo-HSCT since 2003.18–20 We employed these
biomarkers to generate an aGvHD-specific classifier, aGvHD_MS17,
that allowed distinction of patients with severe aGvHD (grades III
and IV) from those who never developed aGvHD, patients with
low or moderate aGvHD (grades I and II) and patients with
chronic GvHD (cGvHD) after allo-HSCT. In the present study,
we prospectively evaluated the predictive value of aGvHD_MS17 in
423 patients who were enrolled in one of five participating
transplant centers and who were transplanted between 2005
and 2010. Results obtained from aGvHD_MS17 analysis were
superior to results for other biomarkers previously described for
prediction or diagnosis of aGvHD, such as loss of serum albumin,21
C-reactive protein22 and plasma biomarkers.23 This report
represents the largest study using proteomics in patient
assessment. Our results demonstrate the predictive value,
clinical usefulness and applicability of this novel diagnostic tool in
post-HSCT surveillance.
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PATIENTS AND METHODS
Patients
Prospectively collected midstream urine samples from 429 patients
undergoing allo-HSCT between 2005 and 2010 were obtained after
informed consent (ethic protocol number 3790). Six patients died before
engraftment and were excluded from further analysis. A summary of all
clinical data is shown in Tables 1a–c. Of 423 recipients, 242 were male,
80 of those were transplanted from female donors and for 16 no
information on donor gender was available. Immunosuppressive anti-
bodies were administered to 308 (72%) patients. For 17 patients, no
information regarding antibody treatment was available. Diagnosis of
aGvHD was based on clinical criteria24 and on histopathology of biopsies, if
available (Tables 1b and c). Diagnosis of cGvHD followed criteria
established in the cGvHD diagnosis and treatment consensus con-
ferences 2007 and 2009 (ref. 25) and adapted to European needs.26
Incidence and severity of acute GvHD and information on biopsies are
summarized in Tables 1b and c. Twenty-five patients died before day
þ 100, six had aGvHD as cause of death. All patients were examined daily
during hospitalization and weekly thereafter for the first 130 days post allo-
HSCT. Clinical aGvHD was assessed according to the aGvHD score from
grade 0 (no sign of GvHD) to IV.24
Urine sample collection and preparation
A volume of 10ml of second morning midstream urine was obtained from
the participants and immediately frozen at  20 1C. Samples were
collected before HSCT, and on days 0 to 35 (þ / 3 days) on a weekly
basis and bimonthly thereafter. Sample preparation was done as
previously described.19 A median of three samples (range 1–10) were
analyzed per patient.
CE-MS analysis and data processing
CE-MS analysis was performed as previously described15,16,19,20 using a
P/ACE MDQ (Beckman Coulter, Fullerton, CA, USA) coupled on-line to a
Micro-TOF MS (Bruker Daltonic, Bremen, Germany). Mass spectral ion peaks
Table 1a. Clinical characteristics of all patientspa
Prospective (n¼ 423)
Age 49 (17–71)
Disease
Acute (AML, ALL and sAML) 268
Chronic (MDS, MPS, CML and CLL) 78
Lymphoma ( MM, NHL and HD) 68
Nonmalignant (AA and PNH) 9
Status
CR 1/CP 1 129
CR 2 or higher 48
no CR (untreated, relapse and refractory) 217
No status (AA, no information) 29
Conditioning
Myeloablative 134
RIC 285
Unknown 4
Graft
PBSC 379
BM 39
CB 5
GvHD prophylaxis
CSA/MTX 197
CSA/MMF 189
TCD 6
Other 29
None 2
Table 1a. (Continued )
Prospective (n¼ 423)
Age 49 (17–71)
Immunosuppressive antibodies
ATG, thymoglobulin 308
Nonea 98
Donor
Related 92
Unrelated 331
HLA match
Matched 333
Mismatched 90
Gender
Female/male 181/242
Male recipient/female donorb 80
Engraftment failure None
Death before day þ 100 25
Abbreviations: AA, severe or very severe aplastic anemia; ALL, acute
lymphatic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte
globulin; BM, bone marrow; CB, cord blood; CLL, chronic lymphatic leukemia;
CML, chronic myeloid leukemia; CP, chronic phase; CR, complete remission;
CSA, cyclosporine A; HD, Hodgkin’s disease; HLA, human leukocyte antigen;
MDS, myelodysplastic; MM, multiple myeloma; MMF, mycophenolate mofetil;
MPS, myeloproliferative syndrome; MTX, methotrexate; NHL, Non-Hodgkin’s
lymphoma; PBSC, peripheral blood stem cell; PNH, paroxysmal nocturnal
hematuria; RIC, reduced intensity conditioning; sAML, secondary AML; TCD,
T-cell depletion (ex vivo: CD34-selection); other, MMF, tacrolimus (FK506),
steroids or different combinations; None, no additional GvHD prophylaxis
(ex vivo T-cell depletion or syngeneic donors). Sixty-three percent of the patients
were transplanted for acute leukemia (n¼ 268), 78 for chronic malignant disease,
68 for lymphomas and 9 for hematopoietic failure syndromes. At the time of
transplantation, 51% (n¼ 217) were not in CR, and for 20 patients information
on disease status before transplantation was not available. Myeloablative
conditioning (n¼ 134; 31%) consisted of total body irradiation (TBI) (12Gy) or
busulfan (16mg/kg body weight (BW)) in combination with cyclophosphamide
(120mg/kg BW). RIC protocols (n¼ 285; 67%) were administered because of
high-risk leukemia,45% blasts in the BM, co-morbidities not allowing standard
conditioning or because of age (460 years). The ‘Flamsa-protocol’ was the most
frequently applied RIC, and it consisted of fludarabine, high-dose cytarabine,
amsacrine, followed by 4Gy TBI and cyclophosphamide and immunosuppres-
sive antibodies as an additional aGvHD prophylaxis. The majority of the patients
received PBSCs (n¼ 379; 89%), 39 received BM and 5 were transplanted with
double CB transplantation. aGvHD prophylaxis consisted of CSA and MTX
(n¼ 197; 46.5%) or MMF (n¼ 189; 44.6%); or other combinations (n¼ 29); ex vivo
CD34-enrichment (TCD) without additional GvHD prophylaxis (n¼ 6), or no
GvHD prophylaxis for other reasons (n¼ 2). Immunosuppressive antibodies were
administered before HSCT (day  3 to  1) to 308 patients (72%). ATG
(Fresenius, Munich, Germany) was administered at 20mg/kg BW per day for
matched unrelated donor or 10mg/kg BW per day for matched related donor.32
Thymoglobulin (Sanofi-Aventis, Paris, France) was administered at 7.5 or
4.5mg/kg BW.33 For 17 patients, no information about administration of
immunosuppressive antibodies was available. Donor and recipients were
matched according to HLA antigens determined by PCR, as described.
Related donors were available for 92 recipients (22%). For related donors, a
low-resolution method, matching HLA-A, -B and DR (6/6), was used, whereas for
unrelated donors, a high-resolution method, matching HLA-A, -B, -C, DQ and DR
(10/10), was employed. The majority of patients were transplanted from
matched donors (n¼ 333; 79%), whereas 90 (21%) received stem cells from
mismatched donors. For 16 male recipients, no information on donor gender
was available. In our cohort, 242 (56%) recipients were male, and 33% (n¼ 80)
received HSCT from female donors. Six of the 429 initial patients were excluded
from further analysis because of death by engraftment failure. Twenty-five
patients died before day 100, six with aGvHD-complications as cause of death.
aFor 17, no information on immunosuppressive antibodies. bFor 16 male
recipients, no information on donor gender.
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representing identical peptides at different charge states were
deconvoluted into molecular mass using MosaVisu software.14 Migration
times and ion signal intensities (amplitude) were normalized using internal
polypeptide standards.27 The resulting peak list characterizes each
polypeptide by its molecular mass (kDa), normalized migration time
(min) and normalized signal intensity. Polypeptides within different
samples were considered identical if the mass deviation was o50 p.p.m.,
and the CE migration time deviation was o2min.19
Adaptation of the aGvHD-specific proteomic pattern and support
vector machine-based cluster analysis
The training set for the aGvHD-specific pattern was published previously19
and expanded here. Thirty-three samples were collected from patients
with biopsy-proven aGvHD grade II or higher at the time of diagnosis
(range: day þ 4 to þ 79). Controls consisted of 76 time-matched samples
of patients without aGvHD and without infections or relapse at the time of
sampling (Supplementary Table S1). All identified discriminatory polypep-
tides were combined to a support vector machine (SVM) classification
model using the MosaCluster software.17 The SVM classifier generates a
dimensionless membership probability value on the basis of a patient’s
peptide marker profile, termed the classification factor (CF).19,20
Statistical methods
Estimates of sensitivity and specificity were calculated based on tabulating
the number of correctly classified samples in receiver operating
characteristic curves and are presented as Box-and-Whisker plots of
group-specific CF distributions. Only samples collected until clinical
diagnosis of aGvHD were included in this evaluation. Confidence intervals
(95%) were based on exact binomial calculations using MedCalc (MedCalc
version 8.1.1.0 software, Mariakerke, Belgium).
Binomial logistic regression analysis was performed to determine the
relationship between proteomic classification with the aGvHD_MS17
model, demographic and clinical data (Table 2).
Peptide sequencing
Urine samples were analyzed on a Dionex Ultimate 3000 RSLS nano flow
system (Dionex, Camberly, UK) as described previously.19 All polypeptides
forming aGvHD_MS17 are shown with their CE-MS characteristics (Table 3)
and sequences. More detailed information and additional data can be
found in the Supplementary Material provided at the journal’s website.
RESULTS
Patient characteristics
In this prospective validation study, 423 patients from five
transplant centers were evaluated with the aGvHD-specific
aGvHD_MS17 peptide marker pattern. A summary of relevant
clinical data is shown in Table 1a and described in Methods.
Table 1b lists the incidence and severity of aGvHD and gives
information on biopsies obtained within our cohort. Acute GvHD
developed in 215 patients (50%). Grade I was diagnosed in 21.5%
(n¼ 89), whereas 17.5% (n¼ 74) had aGvHD grade II. Twelve
percent (n¼ 52) of the patients developed aGvHD III (n¼ 29) or IV
(n¼ 23) despite GvHD prophylaxis and additional immunosup-
pressive antibodies (antithymocyte globulin) (Table 1b). Biopsy
results and proteome analysis at the same time point were
available from 80 patients. aGvHD was histologically confirmed in
70 patients. Of those, 32 had aGvHD grade I or II and 38 had GvHD
grade III or IV. Only the latter were included to the in-depth
analysis. Diagnosis based on biopsy and proteomic profiling is
compared in Table 1b. Table 1c summarizes the data of biopsies
and aGvHD-MS17 diagnostics.
Proteomic patterns (aGvHD_MS17) for aGvHD assessment
The aGvHD_MS17 proteomic classifier was designed to predict
patients at risk for development of severe aGvHD. Quantitative
differences in the excretion of the pattern-forming peptides were
observed upon comparison of patients without aGvHD, patients
with aGvHD grade I and those with biopsy-proven aGvHD grade II
or more sampled at clinical diagnosis of aGvHD (Table 2).
The differences in the excretion of the peptides included in the
proteomic classification model aGvHD_MS17 were converted to
a numerical CF, using an SVM-based clustering software as
described.19 Box-and-Whisker plot analysis of CF values in the case
and control patient groups of the training set (Supplementary
Table S1) demonstrated a significant difference of the
aGvHD_MS17 classifier in samples from patients without aGvHD
or aGvHD grade I (Po0.0001) when compared with patients with
aGvHD grade II or more (Figure 1a). Analyses of 1106 samples
collected from our prospective cohort provided further evidence
that the proteome classifier aGvHD_MS17 can significantly
distinguish patients with no aGvHD from those with aGvHD grade
I (P¼ 0.0004), grade II (Po0.0001) or grades III/IV (Po0.0001),
respectively (Figure 1b). To evaluate the specificity of
aGvHD_MS17, additional control samples including chronic renal
failure syndromes and autoimmune diseases were analyzed with
the same classifier as patients after allo-HSCT (Figure 1c). Only
samples from patients after allo-HSCT with severe aGvHD were
positive in aGvHD_MS17 classification. Organ manifestation of
aGvHD was analyzed in the prospective set for prediction of organ
involvement. aGvHD_MS17 scoring was investigated for skin,
intestine or liver manifestation of aGvHD to examine possible
organ-specific effects on the classification. Although no significant
difference between the different manifestations could be
detected (data not shown), indicating absence of organ specificity
of aGvHD_MS17, involvement of more than 1 organ, which usually
correlated with a higher grade of aGvHD, resulted in higher CF
values (Figure 1d), as expected.
Peptides and proteins forming the aGvHD_MS17 proteomic
pattern
To date, we have successfully sequenced 10 of 17 pattern-forming,
naive peptides. In patients with aGvHD, we found increased
Table 1b. Incidence and severity of acute GvHD after allogeneic HSCT and biopsy and proteomic pattern information
Number of patients Biopsy Biospy-positive aGvHD_MS17-positive Biopsy-negative aGvHD_MS17-negative
aGvHDI 89 20 14 16 6 4
aGvHD II 74 21 18 11 3 10
aGvHD III 29 19 18 17 1 2
aGvHD IV 23 20 20 19 0 1
Total 215 80 70 63 10 17
The incidence and severity of acute GvHD in our patient cohort is summarized. In addition, biopsies available at time points of proteomic analyses were
analyzed. Of 423 patients included in the analysis, 25 died before day þ 100 (aGvHD-related complications were cause of death in six patients). Acute GvHD
was diagnosed in 215 patients (50%), 89 (21%) had aGvHD grade I, 74 (17.4%) and 12% (52) had severe aGvHD (aGvHD III or IV). The number of patients with
biopsies (biopsy), confirmation of clinical diagnosis by biopsy (biopsy positive) or proteomic diagnostic (aGvHD_MS17-positive) and negativity of biopsy
(biopsy-negative) or proteomic diagnostic (aGvHD_MS17-negative) are shown. Twenty-five patients died before day þ 100 (six with aGvHD).
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excretion of fragments of albumin (N-terminal), b2-microglobulin,
collagen-a1 and -a2, and decreased excretion of fragments of
CD99, fibronectin and collagen-a1 (Table 3).
Multivariable logistic regression and receiver operating
characteristic analysis
Consecutive logistic regression analysis using aGvHD grade III or IV
onset 14 days before any clinical signs for aGvHD as a dependent
binary variable (Methods and Table 2) demonstrated that
positivity in the aGvHD_MS17 model was the strongest predicting
variable (Po0.0001) for the development of severe aGvHD.
Recipient gender (P¼ 0.0001) was also a highly significant
predictor in our cohort (Table 2), with a predisposition of aGvHD
development in males. Donor gender (P¼ 0.037) was also a
significant variable; male recipients transplanted from female
donors had the highest risk for aGvHD development. Other
significant variables were age, conditioning (P¼ 0.05), immuno-
suppressive antibodies (P¼ 0.02), primary disease (acute myeloid
leukemia; P¼ 0.046) and days post HSCT (P¼ 0.001). C-reactive
protein and serum albumin did not correlate with aGvHD
development (P-values of 0.72 and 0.07, respectively) and
therefore did not improve classification performance of the
logistic regression model.
A logistic regression model combining the aGvHD_MS17 CF
values with the statistically significant demographic and clinical
variables presented in Table 2 enabled diagnosis of severe aGvHD
with a sensitivity of 82.4% and a specificity of 77.3% about 14 days
before clinical diagnosis and at a time when the patients had no
clinical signs of aGvHD (Figure 2a). CF of 0.1 was determined as
the most discriminatory cut off. Separate analyses of recipients of
bone marrow (BM) grafts (n¼ 39) revealed high sensitivity (83%)
and specificity (93%) for prediction of severe aGvHD development
(Figure 2b). In addition, we compared the proteomics data with
data obtained from biopsies where available. Figure 2c shows the
receiver operating characteristic for both diagnostic tools in
comparison. The prediction of severe aGvHD by aGvHD_MS17
proteomic profiling is comparable to the diagnosis based on
biopsies (Table 1c, Figure 2c). Patients with biopsy-proven aGvHD
grade III/IV were predicted correctly with aGvHD_MS17 with 91%
sensitivity and 80% specificity. In addition, positivity of
aGvHD_MS17 was usually detected earlier than positivity in
biopsies (Table 1c, Figure 2c).
To test the ability of the aGvHD_MS17 pattern to discriminate
between aGvHD and cGvHD, we evaluated samples from patients
with manifested cGvHD and samples collected after day þ 130
post HSCT upon complete withdrawal of immunosuppression.
The aGvHD_MS17 pattern did not cross-react with patients with
manifested cGvHD (Supplementary Figure S1). Late-onset aGvHD
upon withdrawal of immunosuppression was diagnosed using
aGvHD_MS17 and presented as ‘aGvHD’ in our biomarker panel.
The data demonstrate that the combination of aGvHD_MS17 with
relevant demographic and medical variables provides for the first
time the opportunity for preemptive treatment of patients at risk
for severe aGvHD.
DISCUSSION
Evaluation of the aGvHD-specific proteomic pattern aGvHD_MS17
over a period of 5 years in five different transplant centers
demonstrated its power to predict aGvHD and potential useful-
ness to select patients for preemptive therapy. Blinded samples
were classified correctly, with a sensitivity of 82.4% (95%
confidence interval: 71–92.4) and specificity of 77.3% (95%
confidence interval: 73.7–79.2) in combination with demographic
and medical variables using a logistic regression model (Figure 2).
Separate analyses of samples from patients after BM or peripheral
blood (PB) stem cell transplantation showed that the performance
of aGvHD_MS17 was statistically significantly better (P¼ 0.01) in
patients after BM-HSCT (area under the curve: 0.95). The sensitivity
and specificity were 83% and 93% compared with 83% and 76%,
respectively, in the PB-HSCT (area under the curve: 0.84) recipients.
However, only 39 patients received BM-HSCT grafts, whereas 379
received PB-HSCT grafts.
Importantly, the aGvHD_MS17 is specific for prediction of
aGvHD, especially grades III and IV, and does not cross-react with
patients with other diseases or complications tested (Figure 1) or
samples from patients with cGvHD (Supplementary Figure S1).
In addition, aGvHD_MS17 positivity was the most significant
independent variable in the multivariable logistic regression
model, predicting development of aGvHD grades III and IV,
followed by gender, whereas conditioning regimen and even
matched donor transplantation were less significant (Table 2).
The loss of serum albumin in patients developing aGvHD grades
III and IV of the intestine has been described recently, leading the
authors to speculate that albumin might be lost via the intestine
Table 2. Multiparameter logistic regression analysis of demographic and clinical variables for the prediction of aGvHD grade III or IV development
Independent variable Regression coefficienta S.e. Significance level (P)
aGvHD_MS17 CF 0.75 0.16 o0.0001
Age  0.02 0.01 0.050
ATG (no¼ 0, yes¼ 1)  0.83 0.36 0.022
Gender of recipient (female¼ 0, male¼ 1) 1.23 0.31 0.0001
Gender of donor (female¼ 0, male¼ 1)  0.59 0.28 0.037
Conditioning (RIC¼ 0, myeloablative¼ 1)  0.69 0.38 0.05
CRP (mg/l)  0.001 0.003 0.72
Diagnosis (acute leukemia¼ 0, chronic leukemia¼ 1, lymphoma¼ 2, nonmalignant¼ 3)  0.45 0.23 0.046
Donor (related¼ 0, unrelated¼ 1)  0.31 0.33 0.34
HLA match (matched¼ 0, mismatched¼ 1) 0.22 0.34 0.51
Serum albumin (g/l)  0.06 0.05 0.07
Stage (no CR¼ 0, CR 1/CP 1¼ 1, CR42¼ 2) 0.27 0.18 0.14
Days post HSCT  0.018 0.34 0.001
Abbreviations: aGvHD, acute graft-versus-host disease; ATG, antithymocyte globulin; CP, chronic phase; CR, complete remission; CRP, C-reactive protein; HLA,
human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; RIC, reduced intensity conditioning regimen. Multiparameter, logistic regression
analysis is shown to determine the relationship between proteomic classification with the aGvHD_MS17 model, demographic and clinical data as predictor
variables for development of severe aGvHD grades III and IV. Clinical data, such as age and gender of the patient and donor, conditioning regimen (RIC or
standard), presence or absence of immunosuppressive antibodies (ATG or thymoglobulin), primary disease, stage of disease before HSCT, related or unrelated
donors, HLA-matching of donor and recipient, levels of serum albumin (g/l)21 and CRP (mg/l)22 were used in this model. aExpresses the amount of change in
the logit function related to one unit change in the predictor.
Proteomic profiling for diagnosis of aGvHD
EM Weissinger et al
847
& 2014 Macmillan Publishers Limited Leukemia (2014) 842 – 852
Ta
bl
e
3.
C
h
ar
ac
te
ri
st
ic
s
o
f
u
ri
n
e
p
ep
ti
d
es
fo
rm
in
g
th
e
aG
vH
D
_M
S1
7
p
at
te
rn
P
ep
ti
d
e
d
is
tr
ib
u
ti
o
n
in
th
e
tr
a
in
in
g
co
h
o
rt
C
E-
M
S
ch
a
ra
ct
er
is
ti
cs
N
o
G
vH
D
(n
¼
57
)
G
vH
D
g
ra
d
e
I
(n
¼
19
)
G
vH
D
g
ra
d
e
II–
IV
(n
¼
35
)
Se
q
u
en
ce
in
fo
rm
a
ti
o
n
P
ep
ti
d
e
ID
a
C
E
m
ig
ra
ti
o
n
ti
m
e
(m
in
)
M
a
ss
(D
a
)
M
ea
n
a
m
p
Fr
eq
M
ea
n
a
m
p
Fr
eq
M
ea
n
a
m
p
Fr
eq
Se
q
u
en
ce
b
P
ro
te
in
n
a
m
e
A
A
c
36
96
21
.5
4
88
2.
4
77
0.
52
69
0.
51
16
2
0.
71
n
.i.
23
96
8
36
.1
8
11
91
.5
15
2
0.
50
88
0.
38
71
0.
27
p
P
G
SN
G
N
p
G
P
p
G
P
C
o
lla
g
en
a-
1(
II)
ch
ai
n
90
7–
91
9
30
17
7
21
.4
2
12
92
.6
62
0.
23
71
0.
26
17
0.
08
n
.i.
45
50
3
39
.9
8
15
40
.8
83
1
0.
63
94
4
0.
74
14
56
0.
79
G
P
p
G
V
P
G
p
P
G
p
G
G
SP
G
LP
C
o
lla
g
en
a-
1
(X
X
II)
ch
ai
n
71
7–
73
4
82
09
4
19
.8
4
22
28
.1
81
5
0.
15
47
9
0.
30
16
97
0.
59
D
A
H
K
SE
VA
H
R
FK
D
LG
EE
N
F
Se
ru
m
al
b
u
m
in
;
N
-t
er
m
.
25
–4
3
84
12
6
33
.5
5
22
57
.0
55
2
0.
70
29
9
0.
49
58
3
0.
67
Q
G
PA
G
Ep
G
Ep
G
Q
TG
PA
G
A
R
G
PA
G
p
P
C
o
lla
g
en
a-
2(
I)
ch
ai
n
11
4–
13
8
10
0
53
7
20
.0
7
26
03
.3
62
81
0.
27
68
10
0.
40
17
27
4
0.
63
LK
N
G
ER
IE
K
V
EH
SD
LS
FS
K
D
W
S
P
-2
-m
ic
ro
g
lo
b
u
lin
60
–8
1
10
5
83
6
23
.3
8
27
08
.3
18
3
0.
22
33
9
0.
38
94
2
0.
67
K
G
Q
p
G
A
p
G
V
K
G
Ep
G
A
p
G
EN
G
Tp
G
Q
TG
A
R
G
C
o
lla
g
en
a-
2(
I)
ch
ai
n
18
9–
21
7
11
0
84
1
23
.7
1
28
21
.3
24
7
0.
38
36
9
0.
53
76
3
0.
71
Lk
G
Q
p
G
A
p
G
V
K
G
Ep
G
A
p
G
EN
G
TP
G
Q
TG
A
R
G
C
o
lla
g
en
a-
2(
I)
ch
ai
n
18
8–
21
7
11
8
59
7
23
.4
2
30
21
.4
61
1
0.
71
24
7
0.
51
20
2
0.
29
D
G
V
SG
G
EG
K
G
G
SD
G
G
G
SH
R
K
EG
EE
A
D
A
P
G
V
IP
G
C
D
99
an
ti
g
en
97
–1
29
11
9
14
2
24
.9
3
30
33
.4
94
0.
23
32
9
0.
30
40
8
0.
36
LD
G
A
K
G
D
A
G
PA
G
P
K
G
Ep
G
Sp
G
EN
G
A
p
G
Q
M
G
P
R
G
C
o
lla
g
en
a-
1
(I)
ch
ai
n
27
3–
30
5
11
9
53
8
29
.9
8
30
41
.4
19
79
0.
94
16
64
0.
91
92
8
0.
69
D
G
IH
EL
FP
A
P
D
G
EE
D
TA
EL
Q
G
LR
P
G
SE
Y
Fi
b
ro
n
ec
ti
n
16
71
–1
69
8
13
3
50
8
22
.6
9
34
43
.6
15
5
0.
10
24
9
0.
21
10
76
0.
49
n
.i.
14
5
88
9
24
.5
3
38
91
.8
48
7
0.
50
45
4
0.
32
13
4
0.
13
n
.i.
14
8
38
4
19
.4
8
39
95
.9
18
5
0.
10
19
7
0.
17
15
33
0.
37
n
.i.
16
0
24
0
23
.0
0
44
41
.0
36
8
0.
10
30
4
0.
13
14
75
0.
43
n
.i.
16
4
53
9
23
.1
2
46
13
.1
30
7
0.
10
54
4
0.
23
21
54
0.
57
n
.i.
A
b
b
re
vi
at
io
n
s:
A
A
,a
m
in
o
ac
id
;a
m
p
,a
m
p
lit
u
d
e;
C
E-
M
S,
ca
p
ill
ar
y
el
ec
tr
o
p
h
o
re
si
s
co
u
p
le
d
o
n
-l
in
e
to
m
as
s
sp
ec
tr
o
m
et
ry
;G
vH
D
,g
ra
ft
-v
er
su
s-
h
o
st
d
is
ea
se
;F
re
q
,f
re
q
u
en
cy
;n
.i.
,n
o
t
id
en
ti
fie
d
.T
h
e
ta
b
le
g
iv
es
th
e
p
ep
ti
d
e
id
en
ti
fic
at
io
n
n
u
m
b
er
(P
ep
ti
d
e-
ID
),
ex
p
er
im
en
ta
l
m
as
s
(in
D
a)
an
d
C
E
m
ig
ra
ti
o
n
ti
m
e
(in
m
in
)
fo
r
al
l
17
p
ep
ti
d
es
in
cl
u
d
ed
th
e
u
ri
n
ar
y
aG
vH
D
_M
S1
7
p
ep
ti
d
e
m
ar
ke
r
m
o
d
el
.F
o
r
al
l
se
q
u
en
ce
-i
d
en
ti
fie
d
p
ep
ti
d
es
,
th
e
A
A
se
q
u
en
ce
,
th
e
n
am
e
o
f
th
e
p
ro
te
in
p
re
cu
rs
o
r
an
d
th
e
A
A
p
o
si
ti
o
n
s
w
it
h
in
th
e
p
ro
te
in
’s
p
ri
m
ar
y
se
q
u
en
ce
(a
cc
o
rd
in
g
to
U
n
iP
ro
tK
B
)
ar
e
p
re
se
n
te
d
.
In
ad
d
it
io
n
,
th
e
fr
eq
u
en
cy
an
d
th
e
m
ea
n
am
p
lit
u
d
e
in
th
e
n
u
m
b
er
o
f
G
vH
D
,G
vH
D
g
ra
d
e
Ia
n
d
G
vH
D
g
ra
d
e
II–
IV
g
ro
u
p
s
o
f
th
e
tr
ai
n
in
g
co
h
o
rt
ar
e
p
ro
vi
d
ed
.a
Pe
p
ti
d
e
id
en
ti
fic
at
io
n
n
u
m
b
er
s.
b
H
yd
ro
xy
la
ti
o
n
o
f
p
ro
lin
e
an
d
ly
si
n
e
is
in
d
ic
at
ed
in
th
e
am
in
o
ac
id
se
q
u
en
ce
b
y
lo
w
er
ca
se
‘p
’
an
d
‘k
,
re
sp
ec
ti
ve
ly
.
c P
o
si
ti
o
n
s
o
f
fir
st
an
d
la
st
A
A
ac
co
rd
in
g
to
U
n
iP
ro
t
K
n
o
w
le
d
g
e
B
as
e
n
u
m
b
er
in
g
.
Proteomic profiling for diagnosis of aGvHD
EM Weissinger et al
848
Leukemia (2014) 842 – 852 & 2014 Macmillan Publishers Limited
as aGvHD-initiated organ damage progresses.21 The majority of
patients had decreased albumin levels early after HSCT; however,
inclusion of serum albumin levels in our multivariate regression
model showed that serum albumin loss was not statistically
significant in our cohort for prediction of severe aGvHD.
The decreased serum albumin levels observed in our study may
have resulted from the administration of immunosuppressive
antibodies to 72% of our patients during conditioning (Tables 1a–
c). Capillary leakage syndromes are common under this con-
ditioning therapy and may be the underlying cause of serum
albumin loss in our patients independent of aGvHD. However, we
detected increased urinary excretion of a specific N-terminal
fragment of albumin as aGvHD progressed (Table 3). Albumin
uptake in T cells was described to be associated with aGvHD
development.28 Thus, our results confirm those of Rezvani et al.,21
but suggest changes in serum albumin metabolism/catabolism or
possible GvHD-induced vascular damage in the kidney rather than
mere intestinal loss of serum albumin as a pathological
component of aGvHD.
Others have applied new technologies for aGvHD diagnosis,
underlining the need for advances in the ability to diagnose GvHD
in patients undergoing allogeneic HSCT.23,29,30 A biomarker panel
consisting of six proteins potentially involved in the pathogenesis
of aGvHD (IL-2 receptor-a, tumor necrosis factor receptor-1,
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Figure 1. Patients and samples in the model establishment and prospective evaluation phase. (a) Distribution of the CF in the training set.
Box-and-Whisker plot presentation showing the difference in aGvHD_MS17 classification between patients with aGvHD grade II or more
compared with the controls for the training set. The training set consists of 33 samples with aGvHD grade II or more, and 76 samples from
control patients. The pattern was transformed into a CF shown on the y axis using MosaCluster, an SVM-based program. MosaCluster
constructs a separation hyperplane between the case and control samples of the training set in the n-dimensional aGvHD biomarker space.
The result of SVM classification is a dimensionless positive or negative number termed as CF representing the Euclidian distance of a sample
data point to the constructed separation hyperplane. The CF with the best sensitivity–specificity ratio in receiver operating characteristic
evaluation of SVM values of the training set was defined as the cut-off point, in this case CFX0.1, and used subsequently as decision criterion
for aGvHD prediction in all prospectively collected samples. (b) Distribution of the CF in the prospective samples (n¼ 1106). Comparison of
aGvHD_MS17 CF values in the prospective HSCT patient cohort for the differentiation of aGvHD grade I from grade II and 4grade II. All
samples of the prospective cohort were analyzed and correlated with the clinical data. Box-and-Whisker representation of group-specific CF
distribution is shown for the groups ‘no GvHD’, ‘aGvHD grade I’, ‘aGvHD grade II’ and ‘aGvHD grade III/IV’ of the prospective validation cohort
(423 patients, 1106 samples) until clinical diagnosis of aGvHD. For the calculation of P-values, a post-hoc rank test was performed for average
rank differences between the aGvHD grade I reference group and the aGvHD grade II and4grade II case groups after a significant result in
the global Kruskal–Wallis test (Po0.0001). (c) Specificity of aGvHD_MS17. Comparative analysis of aGvHD_MS17 model classification of
samples collected from: NC, normal controls (n¼ 76); NS, patients with nephrotic syndromes (n¼ 253) including minimal change disease
(n¼ 12), focal segmental glomerulosclerosis (n¼ 106), membranous glomerulonephritis (n¼ 55), membranoproliferative glomerulonephritis
(n¼ 4) and IgA nephropathy (n¼ 76); CVD, patients with cardiovascular diseases (n¼ 234) including myocardial infarction (n¼ 87),
atherosclerosis (n¼ 7), hypertension (n¼ 45) and coronary disease (n¼ 95); TU, patients with tumors (n¼ 160) including Kaposi’s sarcoma
(n¼ 68), pancreatic carcinoma (n¼ 11), cholangiocarcinoma (n¼ 68), hepatocellular carcinoma (n¼ 9) and tumors of other origin (n¼ 4); IEM,
patients with inborn error of metabolism (n¼ 239) including type 2 diabetes mellitus (n¼ 78) and Fabry disease (n¼ 161); AI/ID, patients with
autoimmune or inflammatory disorders (n¼ 661) including type 1 diabetes mellitus (n¼ 503), systemic lupus erythematosus (n¼ 18),
cholestasis (n¼ 115) and vasculitis (n¼ 25); GD, patients with genetic diseases (n¼ 118) including autosomal-dominant polycystic kidney
disease (n¼ 71) and polycystic ovary syndrome (n¼ 47). These non-disease-related control groups were compared with samples collected
from patients after allo-HSCT without aGvHD or aGvHD grade I, aGvHD grade II or aGvHD III and IV. (d) Organ involvement in severe aGvHD.
Figure 1d shows the Box-and-Whisker analyses of aGvHD_MS17 scoring for organ involvement in severe aGvHD. Applying proteomic profiling
does not describe involvement of particular organs; however, severity of aGvHD is usually also accompanied by more than one organ
manifestation. Manifestation of aGvHD in specific organs is indicated. GI, gastrointestinal manifestation.
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Figure 2. (a) Prediction of severe aGvHD 14 days before clinical signs in the prospective patient cohort. Receiver operating characteristic (ROC)
curve (bold line, area under the curve (AUC)¼ 0.85) of aGvHD grade III/IV prediction 14 days before any signs of aGvHD by the logistic
regression model that was generated by combining proteomic pattern diagnosis with statistically significant demographic and medical
variables such as age, immunosuppressive antibodies (antithymocyte globulin/thymoglobulin) recipient and donor gender, conditioning
regimen, primary disease, human leukocyte antigen-match of donor and recipient and days post HSCT. Samples taken under steroid therapy
were excluded to prevent confounding effects of steroids of the blinded set (Tables 1a–c, Supplementary Table 1). 95% Confidence intervals
(95% CIs) are indicated by thin, broken lines. (b) Prediction of aGvHD grade II or more: BM-HSCT versus PB-HSCT. Separate analyses of samples
collected from 39 patients after allogeneic BM and 379 patients after PB stem cell HSCT are shown. Only samples of patients with information
on all clinical and demographic variables were analyzed. Cord blood SCT recipients (n¼ 5) were excluded from this analysis. Pending severe
aGvHD was analyzed by application of aGvHD_MS17 positivity in combination with statistically significant demographic and medical
variables. The resulting ROC curve is compared with that of patients after PB-HSCT. The AUCs (0.95 and 0.84, respectively) are shown by the
bold line, and 95% CIs are indicted by dotted lines. (c) Biopsy-proven aGvHD: correlation to prediction of aGvHD by proteomic profiling.
Biopsies of the suspected organ were available in 80 patients. In 10 cases, aGvHD was not confirmed by biopsy (control). Only patients with
biopsy-confirmed aGvHD grades III/IV were included in the analysis. The correlation of aGvHD_MS17 prediction of pending aGvHD with the
later biopsy-confirmed aGvHD is shown here. AUC (0.89) and 95% CI are shown.
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hepatocyte growth factor, IL-8, elafin, a skin-specific marker,23 and
regenerating islet-derived 3-a)31 was established for serum using
enzyme-linked immunosorbent assay. These biomarkers, present
at the time of diagnosis of manifested aGvHD, were investigated
in a multicenter trial to predict treatment response and survival
of patients with aGvHD.30 Sampling was done at diagnosis of
manifested aGvHD and 14 and 28 days after initiation of
treatment, and the pattern could predict response to therapy
and survival. However, these markers are not suitable for
preemptive diagnosis of aGvHD.30 The special value of our
aGvHD-specific classifier (aGvHD_MS17) is its capacity to identify
patients before any clinical signs of developing aGvHD,
independent of organ manifestation and at least 14 days before
clinical manifestation of aGvHD. The aGvHD_MS17 classifier is in
very good agreement with the gold standard for aGvHD diagnosis,
namely tissue biopsies (Tables 1a–c, Figure 2d). Tissue biopsy
cannot be used for routine monitoring requiring repeated
sampling, and its predictive value is therefore not easily
assessable. Prediction of pending severe aGvHD can currently
only be accomplished by the proteomic pattern. No association of
specific organ manifestations of aGvHD was detectable. However,
the severity of pending aGvHD, as well as manifestation of aGvHD
in more than one organ, was both associated with aGvHD_MS17
scoring. In our cohort, patients with severe aGvHD had generally
more than one organ involved in aGvHD, as well as a higher score
in the aGvHD_MS17 classifier (Figure 1d).
Sequencing the naive peptides forming the classifier
(aGvHD_MS17) provided insight into aGvHD pathophysiology
and, ultimately, may help to identify novel potential therapeutic
targets for aGvHD therapy. We observed increased or decreased
excretion of the pattern-forming peptides. For example, increased
b2-microglobulin excretion may indicate cell death as aGvHD
progresses in severity. In addition, we observed increased or
decreased excretion of particular collagen fragments, indicating
very early changes in collagen metabolism, possibly indicating
inflammation and/or early vascular damage that may conse-
quently lead to organ damage. It is well accepted that
conditioning, especially with total body irradiation, leads to an
inflammatory environment, which causes activation of recipient
antigen-presenting cells and donor T cells. CD99, for example, is
an activation marker of T cells, and excretion was decreased as
aGvHD severity increased. One can speculate that in the activation
state (aGvHD) turnover of CD99 may be reduced. Interestingly, the
decreased excretion of the fibrinogen fragment points toward
unsuccessful repair of the microdamages to the vasculature in
patients prone to develop aGvHD III/IV (Table 3).
In summary, application of the proteomic classifier (aGvHD-
MS17) to evaluate allo-HSCT recipients allowed reliable prediction
of specific changes and damages relevant for our understanding
of aGvHD development. Urinary proteomic monitoring introduces
the first unbiased, investigator-independent diagnosis of pending
severe aGvHD and are currently investigated to guide preemptive
treatment of aGvHD_MS17 pattern-positive patients in clinical
trials.
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